ProFibrix Passes Halfway Mark of Patient Enrolment in Pivotal Phase 3 With Fibrocaps™ and Successfully Concludes Safety Review Assessment

Published: Nov 08, 2012

LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)--ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced that the company has enrolled already more than half of the patients in its pivotal Phase III clinical trial with Fibrocaps (FINISH-3). In addition, it successfully concluded a meeting of the Data Monitoring Committee (DMC), an independent expert panel overseeing patient safety and treatment efficacy.

Back to news